Human Growth Hormone Markets: Worldwide Outlook (2018-2022) with Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk and Pfizer Leading - ResearchAndMarkets.com

The human growth hormone market will register a CAGR of almost 4% by 2022.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, January 8, 2019
Information
Tags: 
Health, Pharmaceutical, Growth hormones, Endocrine system, Medicine, Growth disorders, Endocrinology, Neuroendocrinology, RTT, Peptide hormones, Growth hormone therapy, Growth hormone, Gigantism, Endocrine disease
⚠generated by AI ↴
Summary
Key Points: 
  • The human growth hormone market will register a CAGR of almost 4% by 2022.
  • Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period.
  • Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more.
  • The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.


The "Global
Human Growth Hormone Market 2018-2022" report has been added to ResearchAndMarkets.com's
offering.

The human growth hormone market will register a CAGR of almost 4% by
2022.

Increasing incidence and prevalence of growth hormone disorders due to
the growth hormone deficiency is expected to drive the human growth
hormone market over the forecast period. Moreover, various indications
fall under the growth hormone disorders such as turner syndrome, growth
hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many
more.

Strong pipeline of human growth hormone

Many leading companies such as Novo Nordisk, Merck, and Pfizer have a
strong pipeline in their portfolio for treating various growth hormone
disorders. All these factors are expected to drive the global human
growth hormone market during the forecast period.

Poor patient adherence

The poor patient adherence for human growth hormone due to uneasiness
with growth hormone administration will impact the treatment adherence
and results.

Key Players

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY DRUG TYPE

PART 09: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Growth hormone deficiency - Market size and forecast 2017-2022
  • ISS - Market size and forecast 2017-2022
  • Turner syndrome - Market size and forecast 2017-2022
  • PWS - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by application

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

  • Increasing incidence of growth disorders
  • No impact of biosimilar entry into market
  • Advanced technologies

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/mm9bj4/human_growth?w=4

Copyright: 
Copyright Business Wire 2019